EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liquid biopsy in breast cancer: multi-analyte biomarkers, artificial intelligence, and precision oncology from early detection to therapeutic intervention

Aysan Gholami, Alireza Ahmadi, Danial Ahdi, Seyed Hossein Khoshraftar, Sima Mansoori Derakhshan, Mohammad M. Pourseif

Cellular Oncology · 17.11.2026

DOI: 10.1007/s13402-026-01329-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 17.11.2026. Verfasst von Aysan Gholami und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tabriz University of Medical Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Not applicable. This article is a narrative review. Liquid biopsy enables longitudinal profiling of breast cancer biology. ctDNA, CTCs, and EVs provide complementary biological information. ctDNA detection can precede breast cancer relapse by approximately 10–12 months. PADA-1 showed improved PFS with plasma-guided ESR1-directed switching. Multi-analyte approaches may improve prediction beyond single biomarkers. Breast cancer (BC) remains a leading cause of cancer-related mortality, driven largely by tumor heterogeneity, clonal evolution, and therapeutic resistance. Tissue biopsy, while the diagnostic gold standard, offers only a static snapshot of a constantly evolving disease, and repeated sampling is often impractical, particularly in metastatic settings. Liquid biopsy has emerged as a minimally invasive alternative capable of capturing this evolving biology in real time through circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs). This review examines the biological features, analytical technologies, and clinical applications of these analytes in BC, with particular attention to two rapidly evolving areas. First, we discuss how artificial intelligence and machine learning are being applied to multi-analyte liquid biopsy data, from methylation- and fragmentomics-based classifiers for early detection to models integrating ctDNA and CTC information for resistance profiling and treatment-response prediction, while critically examining current limits in clinical validation and interpretability. Second, we address the role of serial ctDNA monitoring in the neoadjuvant setting, where it can refine risk stratification beyond pathologic complete response and identify candidates for early therapeutic escalation, reflected in intervention trials now testing this approach prospectively. We also cover established roles of these analytes in treatment monitoring, minimal residual disease (MRD) detection, resistance tracking, and metastatic disease management, alongside persistent barriers to routine adoption, including limited early-stage ctDNA shedding, clonal hematopoiesis, and inconsistent analytical standardization. As these technologies mature, liquid biopsy is poised to move from a prognostic tool toward one that guides personalized treatment in BC. A precision oncology workflow starts with a blood sample from a breast cancer patient. Liquid biopsy examines circulating tumor DNA, circulating tumor cells, and extracellular vesicles. Genomic, epigenomic, transcriptomic, proteomic, and metabolomic data are then integrated using artificial intelligence to support molecular clustering, therapy selection, response monitoring, and recurrence assessment.

Förderung

  • Tabriz University of Medical Sciences

Zitieren

APA

Gholami, A., Ahmadi, A., Ahdi, D., Khoshraftar, S. H., Derakhshan, S. M., & Pourseif, M. M. (2026). Liquid biopsy in breast cancer: multi-analyte biomarkers, artificial intelligence, and precision oncology from early detection to therapeutic intervention. Cellular Oncology. https://doi.org/10.1007/s13402-026-01329-9

Vancouver

Gholami A, Ahmadi A, Ahdi D, Khoshraftar SH, Derakhshan SM, Pourseif MM. Liquid biopsy in breast cancer: multi-analyte biomarkers, artificial intelligence, and precision oncology from early detection to therapeutic intervention. Cellular Oncology. 2026. doi:10.1007/s13402-026-01329-9

BibTeX
@article{Gholami2026,
  author = {Gholami, Aysan and Ahmadi, Alireza and Ahdi, Danial and Khoshraftar, Seyed Hossein and Derakhshan, Sima Mansoori and Pourseif, Mohammad M.},
  title = {Liquid biopsy in breast cancer: multi-analyte biomarkers, artificial intelligence, and precision oncology from early detection to therapeutic intervention},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01329-9}
}
Kostenlos starten →